ReviewChinese journal of cancer2013
Aberrant promoter CpG methylation and its translational applications in breast cancer.
Review in Chinese journal of cancer, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 56 citations in OpenAlex.
- Selective Estrogen Receptor Modulators' (SERMs) Influence onInternational journal of molecular sciences · 2024Article
- Epigenetic identification of LTBP4 as a putative tumor suppressor in breast cancer.Epigenomics · 2024Article
- Melatonin: A Potential Regulator of DNA Methylation.Antioxidants (Basel, Switzerland) · 2023Review
- Zinc finger and SCAN domain-containing protein 18 is a potential DNA methylation-modified tumor suppressor and biomarker in breast cancer.Frontiers in endocrinology · 2023Article
- Article
- Pterostilbene Changes Epigenetic Marks at Enhancer Regions of Oncogenes in Breast Cancer Cells.Antioxidants (Basel, Switzerland) · 2021Article
- Correlation of MSH2 exonic deletions and protein downregulation with breast cancer biomarkers and outcome in Pakistani women/patients.Environmental science and pollution research international · 2021Article
- Article
- Article
- Transcriptional Factor Yin Yang 1 Promotes the Stemness of Breast Cancer Cells by Suppressing miR-873-5p Transcriptional Activity.Molecular therapy. Nucleic acids · 2020Article
- Paclitaxel Response Can Be Predicted With Interpretable Multi-Variate Classifiers Exploiting DNA-Methylation and miRNA Data.Frontiers in genetics · 2019Article
- Epigenetic silencing of RNF144A expression in breast cancer cells through promoter hypermethylation and MBD4.Cancer medicine · 2018Article
- The tumor suppressor interferon regulatory factor 8 inhibits β-catenin signaling in breast cancers, but is frequently silenced by promoter methylation.Oncotarget · 2017Article
- Article
- Protocadherin 17 functions as a tumor suppressor suppressing Wnt/β-catenin signaling and cell metastasis and is frequently methylated in breast cancer.Oncotarget · 2016Article
- DNA methylation assessment as a prognostic factor in invasive breast cancer using methylation-specific multiplex ligation dependent probe amplification.EXCLI journal · 2016Article
- Methylation Landscape of Human Breast Cancer Cells in Response to Dietary Compound Resveratrol.PloS one · 2016Article
- Artificial light at night: melatonin as a mediator between the environment and epigenome.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2015Review
- E4BP4 is a repressor of epigenetically regulated SOSTDC1 expression in breast cancer cells.Cellular oncology (Dordrecht, Netherlands) · 2014Article
- Epigenetic changes in carcinogenesis of gallbladder.Indian journal of surgical oncology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is a complex disease driven by multiple factors including both genetic and epigenetic alterations. Recent studies revealed that abnormal gene expression induced by epigenetic changes, including aberrant promoter methylation and histone modification, plays a critical role in human breast carcinogenesis. Silencing of tumor suppressor genes (TSGs) by promoter CpG methylation facilitates cells growth and survival advantages and further results in tumor initiation and progression, thus directly contributing to breast tumorigenesis. Usually, aberrant promoter methylation of TSGs, which can be reversed by pharmacological reagents, occurs at the early stage of tumorigenesis and therefore may serve as a potential tumor marker for early diagnosis and therapeutic targeting of breast cancer. In this review, we summarize the epigenetic changes of multiple TSGs involved in breast pathogenesis and their potential clinical applications as tumor markers for early detection and treatment of breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.